[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632482":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":35,"centralContacts":31,"locations":39,"responsibleParty":53,"collaborators":31,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":31,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":75,"whyStopped":31,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"ABBV-295 Part 1","EXPERIMENTAL","Participants will receive subcutaneous doses of ABBV-295 for 12 weeks.",[13],"Drug: ABBV-295",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo for ABBV-295 Part 1","Participants will receive subcutaneous doses of placebo for 12 weeks.",[18],"Drug: Placebo for ABBV-295",{"label":20,"type":10,"description":11,"interventionNames":21},"ABBV-295 Part 2",[13],{"label":23,"type":10,"description":16,"interventionNames":24},"Placebo for ABBV-295 Part 2",[18],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","ABBV-295","Subcutaneous Injections",[9,20],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":31},"Placebo for ABBV-295",[15,23],[36],{"name":37,"affiliation":5,"role":38},"ABBVIE INC.","STUDY_DIRECTOR",[40],{"facility":41,"status":31,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":31},"CenExel Act- Anaheim Clinical Trials \u002FID# 280879","Anaheim","California","92801","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.9145,33.83529,{"lat":51,"lon":50},{"type":54,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100632482","phase-1-a-study-to-assess-adverse-events-tolerability-and-pharmacokinetics-of-subcutaneous-injections-of-abbv-295-in-healthy-adult-japanese-participants-with-overweight-or-obesity-100632482",false,"NCT07514260","A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity","Inclusion Criteria:\n\n* Japanese participant must be first-or second-generation Japanese of full Japanese parentage.\n\n  1. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent.\n  2. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.\n* BMI is ≥ 23.0 to ≤ 35.0 kg\u002Fm2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n\nExclusion Criteria:\n\n* Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.\n* HbA1c ≥ 6.5% and\u002For serum glucose ≥ 126 mg\u002FdL at Screening.\n* Participant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-1, (GLP-1) agonists, Glucagon-like peptide-1\u002Fglucose-dependent insulinotropic polypeptide (GLP-1\u002FGIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.","ALL","18 Years","65 Years",{"count":66,"type":67},24,"ACTUAL","INTERVENTIONAL",[70],"PHASE1","The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.",[73],"Healthy Volunteer",[73,28],"ACTIVE_NOT_RECRUITING","2026-08-12",{"date":78,"type":67},"2026-08-14",{"date":80,"type":67},"2026-03-31",{"date":82,"type":83},"2027-01","ESTIMATED",{"name":5,"class":6},1]